INTRODUCTION {#s1}
============

Lung cancer accounted for 1.8 million new cases and 1.59 million deaths worldwide in 2012 \[[@R1]\]. Adenocarcinoma is the most prevalent histologic type \[[@R2]\]. Epidermal growth factor receptor (EGFR) is one of the mutated proto-oncogenes in lung adenocarcinoma, where a sensitizing EGFR mutation can result in constitutive activation of tyrosine kinase (TK) and phosphorylation of downstream pathways leading to uncontrolled proliferation, invasion and metastasis. The frequency of EGFR sensitizing mutations ranges from 15% of lung adenocarcinoma in Caucasian populations to as high as 50% in Asian populations \[[@R3]--[@R4]\].

A meta-analysis of 13 randomized trials have shown that EGFR TK inhibitors (TKIs) such as gefitinib or erlotinib delay disease progression significantly but do not improve overall survival compared to first line platinum based chemotherapy in Stage IV lung adenocarcinoma harbouring EGFR sensitizing mutations \[[@R5]\]. The lack of overall survival benefit with EGFR TKIs in these randomized trials is most likely due to the use of these EGFR TKIs as second line therapy after progression on first line chemotherapy \[[@R6], [@R7]\]. These trials established EGFR TKIs as first line systemic therapy for patients with Stage IV lung adenocarcinoma harbouring EGFR sensitizing mutations \[[@R8]\].

Currently, there is no defined role of EGFR TKIs for patients with Stage I to III lung adenocarcinoma. Definitive thoracic radiation therapy (TRT) with or without chemotherapy remains one of the recommended curative treatment options \[[@R8]\]. Although in-vitro studies suggest that non-small cell lung cancer (NSCLC) cell lines with EGFR mutations have increased sensitivity to radiation compared to EGFR wild-type cell lines \[[@R9]\], it is unclear if patients harbouring these mutations have improved clinical outcomes when treated with definitive TRT compared with patients with EGFR wild-type status. Hence, we performed a systematic review and meta-analysis of comparative studies to determine the impact of EGFR sensitizing mutations on tumour overall response rates, locoregional and distant disease recurrence rates, recurrence-free and overall survival as well as toxicity outcomes in patients with non-metastatic lung adenocarcinoma treated with definitive TRT with or without chemotherapy. The knowledge gained from our findings may help with patient prognostication.

RESULTS {#s2}
=======

Results of search strategy {#s2_1}
--------------------------

We identified seven comparative studies including 537 patients using the search strategy summarized in Figure [1](#F1){ref-type="fig"} \[[@R10]--[@R16]\]. We screened through 90 records and retrieved 42 full text articles for further assessment. Thirty four articles were excluded as they did not compare the outcomes of the study participants according to their EGFR mutation status. One study was excluded as the participants received adjuvant TRT.

![Results of search strategy](oncotarget-08-109712-g001){#F1}

Characteristics of included studies {#s2_2}
-----------------------------------

The characteristics of the seven included studies are summarized in Table [1](#T1){ref-type="table"}. Five of the included studies were single institutional retrospective cohort studies \[[@R11]--[@R13], [@R15]--[@R16]\] while the other two were retrospective analysis of prospective single arm clinical trials \[[@R10], [@R14]\]. The median sample size was 44 (range 34 to 184). Six studies included only patients with stage III disease treated with TRT \[[@R10]--[@R11], [@R13]--[@R16]\]. All studies tested for the presence of exon 19 deletion or L858R missense mutation in exon 21. For each study, 10 to 45% of patients had EGFR sensitizing mutations. The reported total thoracic radiation dose among the included studies ranged from 40 to 74 Gy. Only two studies required all patients to receive concurrent platinum doublet chemotherapy \[[@R14]--[@R15]\]. There were only two studies that mandated all patients harbouring EGFR sensitizing mutations to receive EGFR TKIs \[[@R10], [@R14]\].

###### Characteristics of included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study        Year published   Study design                                             Sample size   Median age   Stage III (%)   EGFR mutations tested                                   EGFR activating mutation (%)   Total Thoracic RT dose received (EQD2) (Gy)   Received concurrent chemo (%)   Systemic therapy regimens                                                                                                                                                                               EGFR mutant receiving EGFR TKI (%)   Global score
  ------------ ---------------- -------------------------------------------------------- ------------- ------------ --------------- ------------------------------------------------------- ------------------------------ --------------------------------------------- ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ --------------
  Ready        2010             Retrospective analysis of prospective single arm trial   43            NR           100             Exon 19 deletions and mutations in exon 18, 20 and 21   26                             66                                            Not reported                    Induction phase: 2 cycles of Paclitaxel 200mg/m2 plus Carboplatin area under curve 6 every 21 days plus Gefitinib 250mg daily\                                                                          100                                  B1
                                                                                                                                                                                                                                                                                                         Concurrent phase: Gefitinib 250mg daily or weekly Paclitaxel 50mg/m2 with Carboplatin area under curve 2 for 7 weeks\                                                                                                                        
                                                                                                                                                                                                                                                                                                         Maintenance phase: Gefitinib 250mg daily till disease progression or unacceptable side effects                                                                                                                                               

  Li           2011             Retrospective cohort study                               87            NR           100             Exon 19 deletions and mutations in exon 21              45                             40-70                                         59                              Not reported                                                                                                                                                                                            41                                   B2

  Hayashi      2012             Retrospective cohort study                               34            69           97              Exon 19 deletions and mutations in exon 18 and 21       32                             Not reported                                  88                              Not reported                                                                                                                                                                                            Not reported                         C

  Akamatsu     2014             Retrospective cohort study                               44            66           100             Exon 19 deletions and mutations in exon 18, 20 and 21   30                             56-74                                         91                              Cisplatin plus S-1 or Cisplatin plus Vinorelbine or Carboplatin plus Paclitaxel                                                                                                                         77                                   B2

  Komaki       2015             Retrospective analysis of prospective single arm trial   41            NR           100             Exon 19 deletions and mutations in exon 18, 20 and 21   10                             60                                            100                             Concurrent phase: weekly Paclitaxel 45mg/m2 plus Carboplatin area under curve 2 for 7 weeks plus Erlotinib 150mg daily from Tuesday to Sunday.\                                                         100                                  B1
                                                                                                                                                                                                                                                                                                         Consolidation phase: 2 cycles of Paclitaxel 200mg /m2 plus Carboplatin area under the curve 6 every 21 days                                                                                                                                  

  Tanaka       2015             Retrospective cohort study                               104           62           100             Exon 19 deletions and mutations in exon 18, 20 and 21   28                             54-74                                         100                             Carboplatin plus Paclitaxel or Cisplatin plus Vinorelbine or Cisplatin plus Docetaxel or Cisplatin plus S-1 or Cisplatin plus Pemetrexed or Cisplatin plus Irinotecan or Carboplatin plus Vinorelbine   72                                   B1

  Yagaishita   2015             Retrospective cohort study                               184           61           100             Exon 19 deletions and mutations in exon 21              16                             60                                            90                              Cisplatin plus Vinorelbine or Carboplatin plus Paclitaxel                                                                                                                                               69                                   B1
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR: not reported.

Global score: B1, low-moderate risk of bias; B2, moderate-high risk of bias; C, high risk of bias.

Formal critical appraisal of the seven studies showed that the risk of bias was low to moderate in four studies (quality score B1) \[[@R10], [@R14]--[@R16]\], moderate to high in two studies (quality score B2) \[[@R10], [@R13]\] and high in one study (quality score C) \[[@R12]\].

Tumour overall response rates {#s2_3}
-----------------------------

Five studies reported the rates of the partial and complete tumour response. Four studies defined tumour response as per RECIST 1.1 \[[@R11]--[@R12], [@R15]--[@R16]\], while one study used RECIST 1.0 \[[@R13]\]. There was no significant differences in tumour overall response rates (partial + complete response) between EGFR sensitizing mutations and wild type groups (RR 1.17, 95% confidence interval (CI) 0.99 to 1.37, *P* = 0.06; Figure [2](#F2){ref-type="fig"}). There was no statistically significant heterogeneity in the RR for overall response rate (chi square *P* = 0.16, I^2^ = 40%). There were no significant differences in effects on overall response rates between subgroups defined by study design, use of concurrent chemotherapy or EGFR TK inhibitors (Table [2](#T2){ref-type="table"}). The quality of evidence judged by the GRADE approach was deemed to be very low.

![Tumor overall response rates](oncotarget-08-109712-g002){#F2}

###### Subgroup effects on overall response rates

  Subgroup                                                          Patients   Risk Ratio   95% CI         Interaction *P*
  ----------------------------------------------------------------- ---------- ------------ -------------- -----------------
  Study Design                                                                                             
  Retrospective analysis of prospective single arm clinical trial   41         1.09         0.78 to 1.50   0.63
  Retrospective single institution cohort study                     409        1.19         0.98 to 1.45   
  Use of concurrent chemotherapy                                                                           
  Mandatory                                                         145        1.04         0.84 to 1.27   0.22
  Not Mandatory                                                     205        1.27         0.99 to 1.63   
  Use of EGFR TK inhibitors                                                                                
  Mandatory                                                         41         1.09         0.78 to 1.50   0.63
  Not mandatory                                                     409        1.19         0.98 to 1.45   

Loco-regional disease recurrence rates {#s2_4}
--------------------------------------

Five studies reported the rates of loco-regional disease recurrence \[[@R12]--[@R16]\]. Only one study defined loco-regional disease recurrence as recurrence of disease within the RT fields \[[@R16]\]. The other four studies did not define loco-regional disease recurrence although the results were reported \[[@R12]--[@R15]\]. There was no significant differences in loco-regional disease recurrence between EGFR sensitizing mutations and wild type groups (RR 0.65, 95% CI 0.28 to 1.52, *P* = 0.32; Figure [3](#F3){ref-type="fig"}). There was significant heterogeneity among the trial results (chi square *P* = 0.05, I^2^ = 58%). There were no significant differences in effects on locoregional disease recurrence between subgroups defined by study design, use of concurrent chemotherapy or EGFR TK inhibitors (Table [3](#T3){ref-type="table"}). The quality of evidence judged by the GRADE approach was deemed to be very low.
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###### Subgroup effects on loco-regional disease recurrence rates

  Subgroup                                                          Patients   Risk Ratio   95% CI         Interaction *P*
  ----------------------------------------------------------------- ---------- ------------ -------------- -----------------
  Study Design                                                                                             
  Retrospective analysis of prospective single arm clinical trial   41         0.21         0.01 to 2.91   0.38
  Retrospective single institution cohort study                     366        0.72         0.29 to 1.80   
  Use of concurrent chemotherapy                                                                           
  Mandatory                                                         145        0.37         0.15 to 0.91   0.25
  Not Mandatory                                                     262        0.91         0.26 to 3.10   
  Use of EGFR TK inhibitors                                                                                
  Mandatory                                                         41         0.21         0.01 to 2.91   0.38
  Not mandatory                                                     366        0.72         0.29 to 1.80   

Distant disease recurrence rates {#s2_5}
--------------------------------

Five studies reported rates of distant disease recurrence \[[@R12]--[@R16]\]. Only one study defined distant disease recurrence as recurrence of disease outside the RT fields \[[@R16]\]. The other four studies did not define distant disease recurrence although the results were reported \[[@R12]--[@R15]\]. There was no significant differences in distant disease recurrence between EGFR sensitizing mutations and wild type groups (RR 1.46, 95% CI 0.97 to 2.18, *P* = 0.07; Figure [4](#F4){ref-type="fig"}). There was significant heterogeneity among the trial results (chi square *P* = 0.004, I^2^ = 74%). The effect on disease recurrence rates were greater in study that conduct retrospective analysis of a prospective clinical trial than retrospective single institutional studies (RR 2.74 versus (vs) 1.28, interaction *P* = 0.03); greater in studies that mandate the use of concurrent chemotherapy than studies which did not (RR 2.15 vs 1.05, interaction *P* = 0.03); greater in study that mandates the use of EGFR TK inhibitors than studies which did not (RR 2.74 versus (vs) 1.28, interaction *P* = 0.03) (Table [4](#T4){ref-type="table"}). The quality of evidence judged by the GRADE approach was deemed to be very low.

![Distant disease recurrence rates](oncotarget-08-109712-g004){#F4}

###### Subgroup effects on distant disease recurrence rates

  Subgroup                                                          Patients   Risk Ratio   95% CI         Interaction *P*
  ----------------------------------------------------------------- ---------- ------------ -------------- -----------------
  Study Design                                                                                             
  Retrospective analysis of prospective single arm clinical trial   41         2.74         1.59 to 4.69   0.03
  Retrospective single institution cohort study                     366        1.28         0.85 to 1.92   
  Use of concurrent chemotherapy                                                                           
  Mandatory                                                         145        2.15         1.51 to 3.06   0.03
  Not Mandatory                                                     262        1.05         0.61 to 3.06   
  Use of EGFR TK inhibitors                                                                                
  Mandatory                                                         41         2.74         1.59 to 4.69   0.03
  Not mandatory                                                     366        1.28         0.85 to 1.92   

Recurrence free survival {#s2_6}
------------------------

Six studies reported recurrence free survival \[[@R10], [@R12]--[@R16]\]. Four studies defined recurrence free survival as time from 1^st^ day of treatment (either radiation therapy, chemotherapy or both) to disease recurrence or death \[[@R12]--[@R13], [@R15]--[@R16]\]. One study defined recurrence free survival as time from enrolment to disease recurrence or death \[[@R10]\]. One study did not define recurrence free survival although the results were reported \[[@R14]\]. There was no significant differences in disease recurrence free survival between EGFR sensitizing mutations and wild type groups (HR 1.33, 95% CI 0.90 to 1.97; *P* = 0.15; Figure [5](#F5){ref-type="fig"}). There was significant heterogeneity among the trial results (chi square *P* = 0.07, I^2^ = 51%). The effect on recurrence free survival was greater in studies that mandate the use of concurrent chemotherapy than studies than did not (HR 2.47 vs 1.01, interaction *P* = 0.002). There were no significant differences in effects on recurrence free survival between subgroups defined by study design and use of EGFR TKIs (Table [5](#T5){ref-type="table"}). The quality of evidence judged by the GRADE approach was deemed to be very low.
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###### Subgroup effects on recurrence free survival

  Subgroup                                                          Patients   Hazard Ratio   95% CI         Interaction *P*
  ----------------------------------------------------------------- ---------- -------------- -------------- -----------------
  Study Design                                                                                               
  Retrospective analysis of prospective single arm clinical trial   84         1.43           0.65 to 3.16   0.83
  Retrospective single institution cohort study                     366        1.29           0.76 to 2.17   
  Use of concurrent chemotherapy                                                                             
  Mandatory                                                         145        2.47           1.52 to 4.02   0.002
  Not Mandatory                                                     305        1.01           0.74 to 1.38   
  Use of EGFR TK inhibitors                                                                                  
  Mandatory                                                         84         1.43           0.65 to 3.16   0.83
  Not mandatory                                                     366        1.29           0.76 to 2.17   

Overall survival {#s2_7}
----------------

All studies reported overall survival \[[@R10]--[@R16]\]. Two studies defined overall survival as time from enrolment to death \[[@R10], [@R14]\]. Two studies defined overall survival as time from diagnosis to death \[[@R11]--[@R12]\]. Three studies defined overall survival as time from 1^st^ day of treatment (either radiation therapy, chemotherapy or both) to death \[[@R13], [@R15]--[@R16]\]. There was no significant difference in overall survival between EGFR sensitizing mutation and wild-type (HR 0.99, 95% CI 0.75 to 1.29; *P* = 0.92; Figure [6](#F6){ref-type="fig"}). There was no significant heterogeneity among the trial results (chi square *P* = 0.80, I^2^ = 0%). There were no significant differences in effects on overall survival between subgroups defined by study design, use of concurrent chemotherapy or EGFR TKIs (Table [6](#T6){ref-type="table"}). The quality of evidence judged by the GRADE approach was deemed to be very low.
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###### Subgroup effects on overall survival

  Subgroup                                                          Patients   Hazard Ratio   95% CI         Interaction *P*
  ----------------------------------------------------------------- ---------- -------------- -------------- -----------------
  Study Design                                                                                               
  Retrospective analysis of prospective single arm clinical trial   84         1.00           0.52 to 1.94   0.96
  Retrospective single institution cohort study                     453        0.98           0.73 to 1.32   
  Use of concurrent chemotherapy                                                                             
  Mandatory                                                         145        1.57           0.71 to 3.44   0.22
  Not Mandatory                                                     392        0.93           0.69 to 1.24   
  Use of EGFR TK inhibitors                                                                                  
  Mandatory                                                         84         1.00           0.52 to 1.94   0.96
  Not mandatory                                                     453        0.98           0.73 to 1.32   

Adverse events {#s2_8}
--------------

Only one study compared the adverse events outcomes between EGFR sensitizing mutations and wild-type \[[@R14]\]. There was no significant difference in incidence and severity of esophagitis, pneumonitis, skin toxicity and fatigue between the EGFR mutant and wild type groups.

DISCUSSION {#s3}
==========

This meta-analysis showed that there was no difference in overall tumour response rate, recurrence free or overall survival between EGFR sensitizing mutations and wild type groups. However, these findings were based on very low quality evidence.

Our results were consistent with published meta-analyses that demonstrated that EGFR sensitizing mutations were not prognostic for localized NSCLC treated with definitive chemoradiotherapy or surgery \[[@R17]--[@R19]\]. Ochiai and colleagues performed a systematic review and meta-analysis of three retrospective non-randomized comparative studies to determine the impact of EGFR sensitizing mutations in locally advanced NSCLC treated with concurrent chemo-radiotherapy on patterns of recurrence, recurrence-free and overall survival \[[@R17]\]. They found that there was no difference in disease recurrence, recurrence free and overall survival between EGFR mutated and EGFR wild-type NSCLC, but there was a higher incidence of distant disease recurrence rate and lower incidence of locoregional recurrence rate for EGFR mutated NSCLC. We acknowledged that while the results of our review were mostly consistent with findings of the review reported by Ochiai et al., there are some key differences between the two reviews. Firstly, our population of interest is much broader as we included patients treated with definitive thoracic radiation therapy with or without chemotherapy. Secondly, we included a thorough review on the methodological quality of the included studies as well as an appraisal of the summarized evidence which Ochiai et al. did not perform. Thirdly, we used a random effects model to meta-analysed the results of the included studies, whereas Ochiai et al. adopted a fixed effects model. We believe that it is more appropriate to use a random effects model as there were variation in patient characteristics, utilization rate of concurrent chemotherapy or EGFR TKIs and definition of endpoints among the included studies.

Zhang et al. performed a publication based meta-analysis of 16 studies examining the impact of EGFR sensitizing mutations on disease-free and survival outcomes in resected NSCLC \[[@R18]\]. They found that the presence of EGFR sensitizing mutations was not a prognostic factor in patients with resected NSCLC, but the methodologic quality of the included studies was modest. The findings reported by Zhang et al. were recently confirmed by Shepherd and colleagues who evaluated the prognostic and predictive roles of TP53/KRAS and TP53/EGFR co-mutations in 3,533 patients from the LACE (Lung Adjuvant Cisplatin Evaluation) database of randomized trials of adjuvant chemotherapy versus observation in early stage resected NSCLC \[[@R19]\]. They found that EGFR or KRAS and TP53 tumour suppressor co-mutations had no prognostic effect in resected NSCLC.

Guidelines from the College of American Pathologists, International Association for the Study of Lung Cancer, Association for Molecular Pathology and American Society of Clinical Oncology stated that \[[@R20], [@R21]\]EGFR mutation testing should be performed at the time of diagnosis for patients with stage IV disease who are suitable for therapy or at a time of recurrence or progression in patients who originally presented with lower-stage disease but were not previously tested.EGFR mutation testing of tumours at diagnosis from patients presenting with stage I to III disease is encouraged but the decision to do so should be made locally by each laboratory in collaboration with its oncology team.

The benefits of upfront EGFR mutation testing in non-metastatic NSCLC include starting treatment early in patients who experience a recurrence as the molecular information is already available. Secondly biopsy taken when patients recurred or progressed may be of borderline quantity and quality and this may affect the results of EGFR testing. Hence testing on initial specimen may be preferable. The downsides of upfront EGFR mutation testing in non-metastatic NSCLC include the additional cost of performing these tests when the results may not be used to guide management in patients who never relapse after curative intent therapies. Secondly, the role of EGFR TKIs in non-metastatic NSCLC has not been established \[[@R8]\]. We are awaiting results of on-going trials such as RTOG 1306 to help determine whether adding upfront EGFR TKIs to standard concurrent chemo-radiotherapy would benefit patients with unresectable locally advanced EGFR mutated NSCLC \[[@R22]\].

We feel that the strengths of this review are as follows:It addresses an important clinical question;We evaluated the methodologic quality of the included studies as well as the quality of the summarized evidence using published toolsThere was homogeneity among the trial results for overall survival outcomes.

However, the review was limited by:Small number of included studies, all of which were not randomizedQuality of the summarized evidence being very lowInformation gathered from published data rather than individual patient data.

In summary, we conclude that EGFR sensitizing mutations is not a significant prognostic marker for patients with non-metastatic NSCLC undergoing definitive thoracic radiotherapy, with or without chemotherapy.

MATERIALS AND METHODS {#s4}
=====================

Study criteria {#s4_1}
--------------

This meta-analysis incorporated studies comparing the outcomes of interests of patients, with newly diagnosed non-metastatic NSCLC treated with first-line definitive TRT with or without chemotherapy, who were classified according to their EGFR mutation status i.e. EGFR sensitizing mutations versus wild-type status. The EGFR mutations of interest included exon 19 deletions and L858R point mutations in exon 21. We included studies, either in English or Chinese language, where full publication was available.

Search strategy {#s4_2}
---------------

Studies were identified by searching MEDLINE from the date of inception onwards to December 2016. The search strategy included the medical subject headings of "radiotherapy", "lung neoplasms" and "receptor, epidermal growth factor". The results were then hand searched for eligible trials.

Selection of studies and data collection {#s4_3}
----------------------------------------

Three reviewers independently assessed the eligibility of abstracts identified by the search. The full text article of any study that appeared to meet the inclusion criteria were retrieved for closer examination. Disagreements were resolved by consensus.

The same three reviewers extracted the data independently using standardized data collection forms. The data retrieved from the reports include publication details, methodological components, study characteristics such as sample size, interventions, duration of follow up and outcome measures. The data extracted from the studies were entered into the Cochrane Collaboration software (RevMan version 4.2.9; <http://www.cochrane.org>).

Methodologic quality assessment {#s4_4}
-------------------------------

Quality assessment of each study was based on the reporting of the study methods and results namely: adequacy in the definition of the study participants with respect to time, place and person, percentage of participants refusing to participate, accuracy in measurement of outcomes, blinding in the measurement of risk factors and outcomes, whether all important risk factors were included in the analysis and percentage of participants not included in the analysis. A global quality score for each study was determined based on the reviewers' judgement of the importance of these aspects and consequent susceptibility of the results to bias \[[@R23]\].

The quality of a body of evidence for each individual outcome was summarized using the GRADE approach \[[@R24]\]. This approach involved considering the within study risk of bias (methodologic quality), directness of evidence, heterogeneity, precision of effect estimate and risk of publication bias.

Outcomes measures {#s4_5}
-----------------

The main outcomes of interests were:Tumour overall response defined as complete or partial response as per RECIST criteria \[[@R25]\] or investigator defined criteriaLocoregional disease recurrence defined as recurrence of disease proven histologically or radiologically within the radiation fields or investigator defined criteriaDistant disease recurrence defined as recurrence of disease proven histologically or radiologically outside the radiation fields or investigator defined criteriaRecurrence free survival defined as time from diagnosis or start of any anti-cancer treatment till any disease recurrence proven histologically or radiologically or death from any causeOverall survival defined as time from diagnosis or start of any anti-cancer treatment till death from any causeAdverse events defined as per the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 or 4.0 \[[@R26]\] or as per investigator defined criteria

Statistical analysis {#s4_6}
--------------------

For dichotomous outcomes, i.e. tumour overall response, locoregional disease recurrence, distant disease recurrence and adverse events, we extracted the number of patients in each group who experienced the outcome of interest and the number of patients assessed to estimate a risk ratio (RR). The individual study's risk ratios were pooled using the Mantel-Haenszel method \[[@R27]\]. A RR of more than 1 for tumour overall response suggests an advantage for EGFR sensitizing mutations while risk ratio of more than 1 for the other dichotomous outcomes suggests an advantage for EGFR wild-type.

For time-to-event outcomes, i.e. recurrence free survival and overall survival, the log hazard ratios (HR) and their variances for time-to-event data were estimated using published methods when appropriate summary statistics or Kaplan-Meier curves were reported \[[@R28]\]. The individual study log HR and their variances were then combined using the generic inverse variance method \[[@R29]\]. A HR of less than 1 suggests an advantage for EGFR sensitizing mutations.

Statistical heterogeneity among the included studies' results was assessed by visual inspection of forest plots, chi-square tests and I^2^ statistic. A *P* value higher than 0.1 for chi-square test and an I^2^ value of lower than 25% was interpreted as signifying a low level of heterogeneity \[[@R30]\]. All meta-analyses were performed with a random effects model.

Subgroup analysis {#s4_7}
-----------------

Subgroup analyses, determined a priori were performed to determine if the results were influenced by: the use of concurrent chemo-radiotherapy; the use of EGFR TK inhibitors and study design (prospective versus retrospective). Interaction test was used to compare differences between estimates from different subgroups \[[@R31]\].
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